Assessing liver fibrosis without biopsy in patients with HCV or NAFLD

Tavankit Singh; Daniela S Allende; Arthur J McCullough

doi:10.3949/ccjm.86a.17118

Assessing liver fibrosis without biopsy in patients with HCV or NAFLD

Cleve Clin J Med. 2019 Mar;86(3):179-186. doi: 10.3949/ccjm.86a.17118.

Authors

Tavankit Singh¹, Daniela S Allende^{2

3}, Arthur J McCullough^{4

5}

Affiliations

¹ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.
² Director, Hepatobiliary Pathology, Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.
³ Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁴ Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA. mcculla@ccf.org.
⁵ Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

PMID: 30849036
DOI: 10.3949/ccjm.86a.17118

Abstract

Staging of liver fibrosis is increasingly done using noninvasive methods, in some cases obviating the need for liver biopsy. Scores based on laboratory values and demographic variables have been developed and validated for assessing fibrosis in patients with hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD), as have several imaging methods that measure shear-wave velocity, a reflection of fibrosis severity.

Publication types

Review

MeSH terms

Biopsy / methods
Diagnostic Imaging / classification
Diagnostic Imaging / methods
Hepatitis C / diagnosis*
Humans
Liver Cirrhosis* / diagnostic imaging
Liver Cirrhosis* / pathology
Liver* / diagnostic imaging
Liver* / pathology
Non-alcoholic Fatty Liver Disease / diagnosis*
Unnecessary Procedures